The European Society of Cardiology (ESC) cardio-oncology guidelines provide a comprehensive framework for preventing, detecting, and managing heart damage caused by cancer treatments. Published in 2022 and building on earlier position statements, the guidelines formalize something oncologists and cardiologists had been grappling with for years: many effective cancer therapies carry real cardiovascular risks, and those risks need structured management rather than ad hoc responses. The guidelines cover everything from baseline risk scoring before the first dose of chemotherapy to lifelong surveillance of childhood cancer survivors decades after treatment ends.
Risk Stratification Before Treatment Begins
One of the central principles in the ESC framework is that cardiovascular risk should be assessed before a patient starts any potentially cardiotoxic therapy, not after problems appear. A joint position statement from the Heart Failure Association of the ESC and the International Cardio-Oncology Society laid the groundwork by developing practical risk stratification tools tailored to specific drug classes. These proformas cover anthracyclines, HER2-targeted agents like trastuzumab, VEGF inhibitors, kinase inhibitors for chronic myeloid leukemia, multiple myeloma therapies, RAF and MEK inhibitors, and androgen deprivation therapy. The goal is to sort patients into low, medium, high, and very high risk categories so that monitoring intensity and cardioprotective measures can be matched to each patient’s actual vulnerability.1PubMed. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society
What feeds into these risk scores? Pre-existing conditions like hypertension, diabetes, and prior heart disease matter, as do the patient’s age, prior exposure to cardiotoxic agents, and the specific drug regimen planned. A 30-year-old with no cardiovascular history starting a moderate dose of doxorubicin faces a fundamentally different risk profile than a 70-year-old with controlled hypertension who previously received chest radiation. The stratification tools try to capture those differences in a way that clinicians can act on quickly, rather than relying on gut feeling or treating every patient the same way.
Anthracyclines and Direct Heart Muscle Damage
Anthracyclines like doxorubicin and daunorubicin remain among the most widely used and most cardiotoxic cancer drugs. Their damage to heart muscle cells is driven by multiple pathways, including DNA breaks triggered by an enzyme called topoisomerase IIβ and a surge of damaging molecules called reactive oxygen species. These reactive molecules disrupt the cell’s energy-producing structures, stress internal membranes, and release calcium in uncontrolled ways, all of which can push heart muscle cells toward dysfunction or death.2PubMed Central. Molecular mechanisms of anthracycline cardiovascular toxicity The damage is cumulative and dose-dependent, which is why the guidelines emphasize tracking lifetime anthracycline exposure.
The clinical consequence is cardiomyopathy, a weakening of the heart muscle that can progress to heart failure. This can show up during treatment, within the first year after, or sometimes decades later. That delayed presentation is one reason the ESC guidelines push for long-term follow-up even when a patient sails through chemotherapy without immediate cardiac symptoms.
HER2-Targeted Therapies
Trastuzumab and related drugs target the HER2 receptor on cancer cells, most commonly in breast cancer. Unlike anthracycline damage, trastuzumab-related cardiac dysfunction is generally considered reversible if caught early. The drug works partly by blocking a signaling pathway that heart muscle cells also rely on for maintenance, which can lead to a decline in the heart’s pumping ability. Reported rates of this decline vary widely, from about 3% to 27%, depending on the population studied and how cardiotoxicity is defined.3PubMed Central. Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice
The broad range reflects a real uncertainty in the field. Routine cardiac monitoring during trastuzumab treatment is standard practice, but the best frequency and imaging method for that monitoring remain unsettled. Newer approaches like strain imaging and circulating biomarkers can pick up early signs of trouble, though whether acting on those early signals actually improves long-term outcomes still needs more study.4PubMed Central. Cardiotoxicity of HER2-targeted therapies The guidelines recommend regular echocardiography during treatment, with closer monitoring for patients who also received anthracyclines, since the combination amplifies risk considerably.
VEGF Inhibitors and Blood Pressure
Drugs that block vascular endothelial growth factor signaling are used in kidney cancer, liver cancer, thyroid cancer, and several other malignancies. Their most common cardiovascular side effect is hypertension, which can develop quickly and substantially. In a study of 228 patients, anti-VEGF tyrosine kinase inhibitors raised systolic blood pressure by an average of about 8.5 mmHg and diastolic by about 6.7 mmHg. Axitinib was the worst offender, with systolic increases averaging roughly 12.6 mmHg.5PubMed. Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
This matters because uncontrolled hypertension during cancer treatment can lead to dose reductions or treatment interruptions, and it also raises the risk of stroke, heart failure, and kidney damage. The ESC guidelines recommend proactive blood pressure management in all patients starting VEGF-pathway drugs, including pre-treatment baseline readings and a plan to start or intensify antihypertensive medications promptly. Calcium channel blockers and potassium-sparing diuretics were associated with the largest blood pressure reductions in that same study, which aligns with the guideline preference for those classes in this setting.6PubMed. Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
Immune Checkpoint Inhibitor Myocarditis
Immune checkpoint inhibitors have transformed cancer treatment by unleashing the immune system against tumors. The flip side is that an unleashed immune system can attack healthy tissue, including heart muscle. Immune-related myocarditis is rare but potentially fatal, and the ESC guidelines treat it as a medical emergency. Diagnosis relies on a combination of cardiac biomarkers like troponin, electrocardiography, echocardiography, and cardiac MRI, with tissue biopsy reserved for uncertain cases.7PubMed Central. Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge
Treatment centers on high-dose corticosteroids, which have been shown to reduce the risk of serious cardiac complications. The harder question is what happens afterward: can the patient restart immunotherapy? The evidence is limited but no longer purely anecdotal. Highly selected patients may be rechallenged under close cardio-oncology surveillance, though the guidelines stress that multicenter prospective studies are needed to define safe restart thresholds and monitoring requirements.8JACC: CardioOncology. Rechallenge After Immune Checkpoint Inhibitors Myocarditis: Evidence and a Practical Framework
Proteasome Inhibitors in Multiple Myeloma
Proteasome inhibitors are a backbone of multiple myeloma treatment, but they carry distinct cardiovascular risks. Carfilzomib, an irreversible proteasome inhibitor given intravenously, has a more severe cardiac toxicity profile than bortezomib or ixazomib. Its effects span heart failure, hypertension, arrhythmias, and acute coronary syndromes.9PubMed Central. Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies
An analysis of the FDA’s adverse event database found that heart failure was the most common cardiotoxic event linked to carfilzomib, and roughly two-thirds of those events were classified as serious. Hypertension was the second most frequent problem, with a median onset of just 8 days after starting the drug. When compared against other proteasome inhibitors, carfilzomib showed a substantially stronger association with hypertension, QT prolongation, and heart failure.10PubMed Central. Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS) A clinical study found that cardiac events occurred in about 27% of carfilzomib-treated patients compared to 16% with bortezomib, though the difference did not reach statistical significance in that cohort. A prior history of cardiac events and longer duration of therapy were identified as independent risk factors.11PubMed Central. Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
Androgen Deprivation Therapy and Metabolic Risk
Androgen deprivation therapy for prostate cancer works by suppressing testosterone, which effectively slows tumor growth. But testosterone also plays roles in maintaining muscle mass, insulin sensitivity, and lipid balance. Suppressing it can trigger a cluster of metabolic changes including insulin resistance, elevated triglycerides, reduced HDL cholesterol, and hypertension, all of which raise cardiovascular risk over time.12PubMed Central. Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer Newer androgen receptor pathway inhibitors, such as abiraterone, appear to add incremental cardiovascular risk on top of standard androgen deprivation.13PubMed Central. Cardiovascular Risk in Prostate Cancer Meta-analyses of both randomized trials and observational studies have identified abiraterone as standing out for increasing the risk of cardiac events.14PubMed Central. Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses
The ESC guidelines recommend aggressive management of traditional cardiovascular risk factors in men on long-term androgen deprivation: monitoring glucose and lipids, treating hypertension, encouraging physical activity, and maintaining a healthy weight. Because these metabolic changes develop gradually, they can be easy to overlook in the context of cancer care, where the focus is understandably on tumor control.
Radiation-Induced Heart Disease
Chest-directed radiation can damage every structural component of the heart, leading to coronary artery disease, valve problems, conduction abnormalities, cardiomyopathy, and pericardial disease. The damage is largely driven by fibrosis and tends to emerge years or even decades after treatment.15PubMed Central. Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology This long latency makes surveillance tricky. The American Society of Echocardiography recommends that patients who received more than 35 Gy to the chest get a screening echocardiogram or coronary CT scan about five years after treatment, followed by repeat screening every five years if no problems are found.16Exploration of Medicine. Contemporary review: recognition, management, and screening for radiation-induced heart disease – Section: Screening recommendations in RIHD
Modern radiation techniques that minimize cardiac exposure have likely reduced the incidence of severe heart disease in newly treated patients, but the large population of survivors treated with older techniques remains at risk. The guidelines emphasize that physicians should manage conventional risk factors like cholesterol and blood pressure aggressively in this group, since radiation damage and atherosclerosis compound each other.
CAR T-Cell Therapy
Chimeric antigen receptor T-cell therapy, one of the newest weapons against blood cancers, brings its own cardiovascular concerns. Patients treated with CAR T cells can develop cardiovascular and pulmonary complications, primarily in the setting of cytokine release syndrome, the inflammatory storm that occurs as the engineered cells activate.17PubMed Central. How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy The most common cardiac effects are rapid heart rate and low blood pressure, but more serious events like QT prolongation, ventricular arrhythmias, atrial fibrillation, and even cardiogenic shock have been documented.18European Heart Journal. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies The guidelines recommend cardiac assessment before CAR T-cell infusion and close hemodynamic monitoring during and after the procedure, with particular vigilance in patients with pre-existing cardiac conditions.
How Cardiotoxicity Is Monitored
The ESC guidelines place heavy emphasis on monitoring, both through blood biomarkers and imaging. Troponin, the protein released when heart muscle cells are injured, has become a key tool for detecting damage from anthracyclines, HER2-targeted agents, VEGF inhibitors, and checkpoint inhibitors. It is useful at baseline for risk assessment, during treatment for early detection, and as a trigger for starting protective medications.19PubMed Central. The Value of Troponin as a Biomarker of Chemotherapy-Induced Cardiotoxicity B-type natriuretic peptide (BNP) and its cousin NT-proBNP serve a complementary role. Elevated levels of either biomarker have been linked to increased mortality in cancer patients and can predict the development of heart failure.20PubMed Central. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity
On the imaging side, global longitudinal strain has emerged as a sensitive early marker. This echocardiographic measurement picks up subtle changes in how the heart muscle contracts along its long axis, often before the traditional measure of pumping function (the ejection fraction) drops noticeably. The ESC guidelines recommend a relative decrease in strain of more than 15% during treatment as the threshold for suspecting subclinical cardiac dysfunction.21PubMed Central. Global Longitudinal Strain in Cardio-Oncology: A Review Catching damage at this earlier stage allows clinicians to start cardioprotective medications and, in many cases, avoid interrupting cancer treatment.22PubMed Central. Strain Imaging in Cardio-Oncology Cardiac MRI offers even more detail, including the ability to detect inflammation, fibrosis, and microcirculatory problems, and is particularly valuable in suspected checkpoint inhibitor myocarditis.23PubMed. The Role of Cardiac Magnetic Resonance Imaging to Detect Cardiac Toxicity From Cancer Therapeutics
Prevention Strategies
Preventing cardiotoxicity is always preferable to treating it after the fact, and the guidelines outline several evidence-based approaches. Dexrazoxane, a drug given before anthracycline infusions, substantially reduces the risk of clinical heart failure. A meta-analysis in breast cancer patients found it cut the risk of heart failure by roughly 80% and reduced cardiac events overall by about two-thirds, without compromising tumor response rates, overall survival, or progression-free survival.24PubMed Central. Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer The drug’s protective mechanism turns out to involve blocking topoisomerase IIβ, the same enzyme through which anthracyclines damage heart cells, rather than the metal-chelation mechanism originally assumed.25PubMed. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation
Standard heart failure medications also have a preventive role. A systematic review and meta-analysis of breast cancer patients found that ACE inhibitors, angiotensin receptor blockers, and beta-blockers all helped preserve heart function during anthracycline-based chemotherapy. The effect was statistically significant for each drug class individually and for combinations.26PubMed Central. ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis The guidelines suggest considering these medications for patients stratified as high or very high risk before treatment starts.
Exercise is an underappreciated cardioprotective tool. A meta-analysis focused on breast cancer patients undergoing chemotherapy found that physical training preserved global longitudinal strain compared to sedentary controls, and the benefit was strongest when exercise happened concurrently with chemotherapy rather than after it ended.27PubMed. New insights into cardioprotection in breast cancer patients undergoing physical exercise during chemotherapy: A systematic review and meta-analysis The evidence supports recommending structured exercise programs during treatment as part of a comprehensive cardioprotective strategy, not just as general wellness advice.28PubMed Central. Exercise training in cancer related cardiomyopathy
Treating Cancer-Related Heart Failure
When cardiotoxicity does develop despite preventive efforts, the guidelines follow standard heart failure treatment principles with some cancer-specific nuances. An emerging area of interest is SGLT2 inhibitors, drugs originally developed for diabetes that have become a pillar of heart failure management. A study of patients with cancer therapy-related cardiac dysfunction found that adding an SGLT2 inhibitor to standard heart failure medications was associated with roughly half the risk of acute heart failure flare-ups, about a 70% lower risk of death from any cause, and fewer hospitalizations, arrhythmias, and kidney injuries.29PubMed. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction While this is still a developing area, it suggests that the benefits of SGLT2 inhibitors seen in general heart failure populations extend to cancer patients with treatment-related cardiac damage.
Anticoagulation When Platelets Are Low
One of the trickiest scenarios in cardio-oncology is managing atrial fibrillation in a cancer patient whose chemotherapy has driven platelets dangerously low. Atrial fibrillation normally calls for blood thinners to prevent stroke, but severe thrombocytopenia dramatically raises the risk of bleeding. Studies examining this dilemma in patients with blood cancers and platelets below 50,000 per microliter found that the bleeding risk during these periods may outweigh the stroke-prevention benefit. In one cohort, clinically relevant bleeding occurred in nearly 17% of patients whose anticoagulation was paused, but only about 2% had a blood clot, and rates in patients who continued blood thinners were not clearly better.30PubMed. Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy The ESC guidelines acknowledge that temporarily pausing anticoagulation during severe thrombocytopenia may be reasonable, though decisions need to be individualized.31PubMed. Anticoagulation in cancer patients with atrial fibrillation and grade 3-4 thrombocytopenia
Childhood Cancer Survivors and Lifelong Risk
Children treated for cancer face a unique and sobering situation. Their cardiovascular risks from treatment are amplified by the fact that they were exposed at a young age and have decades ahead for damage to accumulate. Systematic reviews confirm that long-term risks of cardiovascular and metabolic diseases are significantly elevated in childhood cancer survivors, shaped by the type of cancer, the treatment received (anthracyclines and radiation carry the highest risk), and demographic factors like age and sex at treatment.32PubMed Central. Long-Term Cardiovascular Outcomes in Childhood Cancer Survivors: A Systematic Review Many survivors have measurable cardiac abnormalities but no symptoms, which makes the case for lifelong surveillance hard to argue with.
The American Heart Association has highlighted that nearly all cancer treatments pose some cardiovascular risk, and that pediatric patients may be especially vulnerable because of their young age at treatment and the long life span expected afterward.33PubMed Central. Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association Personalized risk prediction models are being developed to help clinicians decide who needs the most intensive follow-up. These models use treatment exposure data (cumulative anthracycline dose, chest radiation fields) along with traditional cardiovascular risk factors that accumulate during the decades after treatment.34PubMed Central. Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention The transition from pediatric to adult cardio-oncology care is a recognized weak point where patients can fall through the cracks.
The Case for Multidisciplinary Cardio-Oncology Programs
Implementing the ESC guidelines in practice requires collaboration between oncologists and cardiologists, which is easier said than done in many hospital systems. Data from a Taiwanese program illustrates the benefit. Among patients receiving anthracyclines without a structured cardio-oncology program, heart pumping function dropped progressively as doses accumulated, falling from about 75% before treatment to about 67% afterward. After the hospital established a multidisciplinary cardio-oncology program, that decline was blunted: function held closer to 70%, and no patients needed to stop anthracycline therapy due to cardiac concerns.35ESC Heart Failure. The Impact of a Multidisciplinary Cardio-Oncology Programme on Cardiovascular Outcomes in Taiwan The difference came down to systematic screening, earlier referral to cardiologists, and proactive initiation of protective medications when early signs of trouble appeared. In a field where the stakes are both cancer survival and long-term heart health, that kind of structured coordination is what the ESC guidelines are ultimately designed to enable.